Press Releases

Date Title
Jan 18, 2022 Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research
DURHAM, N.C. , Jan. 18, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that a peer-reviewed article entitled, “Phase 2 Study of
Jan 03, 2022 Chimerix to Present at Virtual H.C. Wainwright BioConnect 2022 Conference
DURHAM, N.C. , Jan. 03, 2022 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Company management, including Mike Sherman , Chief
Displaying 21 - 22 of 22
  • Print
  • Email Alerts
  • RSS Feeds
  • Search
  • Share